While some look to outcomes-based contracts as a fix for high drug prices, insurers and experts say the alternative models have ultimately made little progress since their introduction, Modern Healthcare reports.
According to the report, policymakers are increasingly looking more toward increased competition as a solution.
“Attention has really shifted to increasing competition and addressing some of the market issues rather than trying to negotiate additional discounts under the status quo,” Pew Charitable Trusts’ Sean Dickson tells Modern Healthcare.
However, there remains confidence that newer types of outcomes-based arrangements can decrease the cost burden of specialty drugs and gene therapies.
To read the full report on Modern Healthcare, click here.